Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy

Journal of Immunotherapy

Volumn 25, Issue 2, 2002, Pages 97-138

  Keilholz, Ulrich ^a   Weber, Jeffrey ^a   Finke, James H ^a   Gabrilovich, Dmitry I ^a   Martin Kast, W ^a   Disis, Mary L ^a   Kirkwood, John M ^a   Scheibenbogen, Carmen ^a   Schlom, Jeff ^a   Maino, Vernon C ^a   Kim Lyerly, H ^a   Lee, Peter P ^a   Storkus, Walter ^a   Marincola, Franceso ^a   Worobec, Alexandra ^a   Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cancer vaccines; Immunologic monitoring; Immunotherapy

Indexed keywords

ANTIBODY; CANCER VACCINE; CYTOKINE; TETRAMER;

ACCURACY; ANALYTIC METHOD; B LYMPHOCYTE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MONITORING; DRUG POTENCY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; HELPER CELL; HUMAN; INTERMETHOD COMPARISON; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MEDICAL SOCIETY; METHODOLOGY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0036199280     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200203000-00001     Document Type: Conference Paper

References (278)

1. Characterization of tumor vaccines during product development
2. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
3. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
4. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to In Vitro stimulation but does not lead to tumor registration
5. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
6. Melanoma vaccines: The paradox of T cell activation without clinical response
7. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
8. In vivo tracking of tumor-specific T cells
9. T cell clonal anergy
10. The anatomy of T-cell activation and tolerence
11. Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics
12. The role of B7-1/B7-2:CD28/CTLa-4 pathways in the prevention of anergy, induction of production immunity and downregulation of the immune response
13. + T-cell tolerance to T-cell priming through in vivo ligation of CD40
14. + T Cells or CTL immunotherapy of tumors expressing the antigen
15. Assessing CD8 T Cell number and dysfunction in the presence of antigen
16. Mechanisms of interleukin-10-mediated immune suppression
17. Type I and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
18. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
19. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunologic dysfunction in advanced cancer patients
20. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
21. + cells in peripheral blood
22. TGF-beta contributes to the shift toward TH2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice
23. TGF-β-based immunotherapy for cancer: Breaching the tumor firewall
24. Regulation of TGF-beta response during T cell activation is modulated by IL-10
25. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response
26. Regulation of tumor growth and metastasis by interleukin-10: The melanoma experience
27. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells
28. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness
29. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice
30. Diagnostic and therapeutic immunology of renal cell cancer
31. Molecular mechanisms of immune dysfunction in renal cell carcinoma
32. Alteration of signal transduction in T cells from cancer patients
33. New insights into T-cell antigen receptor structure and signal transduction
34. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer
35. Expression of signal-transducing zeta chain in peripheral blood T cels and natural killer cells in patients with Hodgkin's disease in different phases of the disease
36. Absent or low expression of the s chain in T cells at the tumor site correlates with poor surival in patients with oral carcinoma
37. Hydrogen peroxide secreted by tumor-specific T cell-and natural killer cell-mediated cytotoxicity
38. Activated granulocytes and gralulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-Cell function in advanced cancer patients
39. Tumor-induced apoptosis of T lymphocytes: Elucidation of intracellular apoptotic events
40. Caspase-mediated degradation of T-cell receptor zeta-chain
41. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma
42. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and downregulation of TCR Zeta molecules in patients with gastric cancer
43. CD30 and CD28 down-modulation on CD8 T cells during viral infection
44. Prolonged exposure of T cells to TNF downregulates TCR and expression of the TCR/CD3 complex at the cell surface
45. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors
46. Gradual Loss of T-Helper 1 populations in spleen of mice during progressive tumor growth
47. Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma
48. NF-kappaB and the innate immune response
49. Preferential role for NF-κB/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo
50. Inhibition of activated/memory (CD45RO+) T cells by oxidative stress associated with block of NFκB activation
51. Renal cell carcinoma-derived galgliosides suppress nuclear factor-kB activation in T cells
52. Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function
53. + T cells exposed to peripheral self-antigens
54. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
55. Mechanisms responsible for signaling and functional defects
56. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
57. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
58. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: Role of nuclear factor-kappaB suppression
59. Death the Fas way: Regulation and pathophysiology of CD95 and its ligand
60. Fas-mediated suicide of tumor-reactive T cells after activation by specific tumor: Selective rescue by caspase inhibition
61. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
62. The role of Fas/FasL in immunosuppression induced by human tumors
63. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens
64. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors
65. Mechanisms of tumor-induced immunosuppression: Evidence for contact-dependent T cell suppression by monocytes
66. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation
67. Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony-stimulating factors and without engagement of host T cells
68. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor
69. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells
70. Resection of solid tumors reverses T cell defects and restores protective immunity
71. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer
72. The biology of vascular endothelial growth factor
73. Dendritic cells in antitumor immune responses: Defective antigen presentation in tumor-bearing hosts
74. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue
75. Clinical significance of defective dendritic cell differentiation in cancer
76. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1
77. Vascular endothelial growth factor effects on nuclear factor-kappa B activation in hematopoietic progenitor cells
78. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappaB activation in hemopoietic progenitor cells
79. Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
80. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
81. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10
82. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony-stimulating factor
83. Human prostate cancer blocks the generation of dendritic cells from cd34+ hematopoietic progenitors
84. T-cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function
85. Apoptotic death of CD8+ T lymphocytes after immunization: Induction of a suppressive population of Mac-1+/Gr-1+cells
86. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells
87. CD28/B7 system of T cell costimulation
88. Alterations in T cell receptor and signal-transduction molecules in melanoma patients
89. Alterations in expression and function of signal-tranducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma
90. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apopotosis and downregulation of TCR zeta molecules in patients with gastric cancer
91. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody
92. Immunological effects of BCG as an autologous tumor vaccines
93. New insights into T-cell antigen receptor structure and signal transduction
94. Signaling defects in T lymphocytes of patients with malignancy
95. Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes
96. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
97. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma
98. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
99. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR-zeta expression but are functionally impaired
100. Restoration of expression of signal-tranduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy
101. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
102. Transmission of signals from the T lymphocytes antigen receptor to the genes responsible for cell proliferation and immune function: The missing link
103. Alterations in NFkB activation in T lympocytes of patients with renal cell carcinoma
104. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules
105. Tumor cells regulate the lyric activity of tumor-specific cytotoxic T lymphocytes by modulation the inhibitory natural killer receptor function
106. Control of apoptosis by Rel/NFkB transcription factors
107. Immunological Correlates for Efficacy of Combination Vaccines
108. Antigenic responses to booster dose of diptheria and tetanus toxoids: Seven to thirteen years after primary inoculation of noninstitutionalized children
109. In vitro anti-HBs production by indiviual B cells of responders to hepatitis B vaccine who subsequently lost antibody
110. Generation of cytotoxic T-cell responses with synthetic melanoma- associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
111. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see comments]
112. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer
113. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcino-embryonic antigen
114. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay
115. Enzyme-linked immunoassays
116. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine
117. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay
118. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy
119. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
120. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
121. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients
122. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
123. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women
124. Immunology and immunotherapy of melanoma
125. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
126. Lymphokine control of in vivo immunoglobulin isotype selection
127. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae
128. B cell stimulatory factor-1 enhances the IgE response of tipopolysaccharide-activated B cells
129. The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype
130. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen
131. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide versus recombinant poxvirus vaccines
132. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
133. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma
134. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry
135. A T cell clone's avidity is a function of its activation state
136. Unique T cell effector functions elicited by plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays
137. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay
138. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients
139. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
140. The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects
141. Rapid cotorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
142. A simple, rapid and sensitive fluorimetric assay for the measurement of cell-mediated cytotoxicity
143. A novel one-step, highly sensitive fluorometric assay to evaluate cell- mediated cytotoxicity
144. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
145. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
146. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
147. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells
148. Quantification of antigen specific CD8+ T cells using an ELISPOT assay
149. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens
150. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells
151. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
152. A comparison between ELISPOT methods for the detection of cytokine producing cells: Greater sensitivity and specificity using ELISA plates as compared with nitrocellulose membranes
153. 280-288 peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
154. Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function
155. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor-α spots in response to peptide antigens
156. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses
157. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity
158. Quantitation of antigen-reactive T cells in peripheral blood by IFN-γ ELISPOT assay and chromium-release assay: A four-center comparative trial
159. Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations
160. Evaluation of tide vaccine immunogenicity in draining lymph nodes and peripheral pep-blood of melanoma patients
161. Application of the IFN-γ-ELISPOT assay to quantify T cell responses against proteins
162. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma
163. Immunization of patients with melanoma peptides vaccines: Immunologic assessment using the ELISPOT assay
164. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay
165. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
166. Rapid effector function in CD8+ memory T cells
167. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
168. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
169. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy
170. A phase I trial of a recombinant vaccinia virus expressing prostate specific antigen in advanced prostate cancer
171. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecules
172. Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
173. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunologic esponse to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
174. Stimulation of CD8+ T-cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine
175. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
176. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
177. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
178. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigne in patients with colorectal cancer
179. 254-262 in melanoma
180. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NYESO-1-expressing melanoma
181. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients
182. Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
183. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-posifive tumors
184. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans after intranodal injection
185. Association between CEA-sepcific T-cell responses (TCR) after treatment with vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients (Pts) with CEA-bearing cancers
186. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry
187. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry
188. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells
189. Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: Efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry
190. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression
191. Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens
192. T-cell epitope mapping by flow cytometry
193. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
194. Viral immune evasion due to persistence of activated T cells without effector function
195. Analysis of CD8 T cell reactivity to cytomegalovirus using protein- spanning pools of overlapping pentadecapeptides
196. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
197. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
198. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen
199. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency vires type -infected patients with high CD4+ T cell counts and recurrent retinitis
200. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects
201. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry
202. Immunofluorescence analysis of T-cell responses in health and disease
203. Flow cytometric measurement of intracellular cytokines detects immune responses in MUCI immunotherapy
204. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
205. Putative immunodominant human immunodeficiency vires-specific CD8(+) T- cell responses cannot be predicted by major histocompatibility complex class I haplotype
206. Maintenance of large numbers of virus-specific CD8+ T cells in HIV- infected progressors and long-term nonprogressors
207. CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens
208. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
209. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis
210. Measurement of anti-human cytomegalovims T cell reactivity in transplant recipients and its potential clinical use: A mini-review
211. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65
212. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy
213. Clonotypic structure of the human CD4(+) memory T cell response to cytomegalovirus
214. Rapid determination of Epstein-Barr vires-specific CD8(+) T-cell frequencies by flow cytometry
215. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma
216. Analysis of successful immune responses in persons infected with hepatitis C virus
217. Detection of Mycobacterium-specific interferon-gamma-producing human T lymphocytes by flow cytometry
218. Application of the intracellular gamma interferon assay to recalculate the potency of CD8(+) T-cell responses to herpes simplex vires
219. A longitudinal study of in vitro IFNgannna production and cytotoxic T cell responses of tuberculosis patients in the gambia
220. High frequency of circulating HBcAg-specific CD8 T cells in hepatitis B infection: A flow cytometric analysis
221. Quantitative analysis of hepatitis C vires-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
222. Direct functional analysis of epitope-specific CDS+ T cells in peripheral blood
223. Long-term CD4 Th1 and Th2 memory after acute lymphocytic choriomeningitis virus infection
224. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
225. Requirements for the maintenance of Thl immunity in vivo after DNA vaccination: A potential immunoregulatory role for CD8+ T cells
226. Control of SlY rebound through structured treatment interruptions during early infection
227. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
228. Direct detection of cellular immune responses to cancer vaccines
229. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers
230. Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset
231. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: Direct detection of immunodominant antigen-responsive cells
232. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
233. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex
234. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
235. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens
236. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
237. Critical role for Cd8 in binding of Mhc tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
238. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers
239. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
240. Kinetics of TCR use in response to repeated epitope-specific immunization
241. Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading
242. Negative selection during the peripheral immune response to antigen
243. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
244. The usefulness of quantitative real time PCR in immunogenetics
245. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: Validation of a new real-time TR-PCR technology
246. Real-time reverse transcription-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I
247. High fidelity mRNA amplification for gene profiling using cDNA microarrays
248. Short-term kinetics of tumor antigen expression in response to vaccination
249. cDNA microarrays and the enigma of melanoma immune responsiveness
250. Laser capture microdissection
251. Quantitative analysis of cytomegalovirus load using a real-time PCR assay
252. Quantification of human cytomegalovirus DNA by real time PCR
253. A rapid real time quantitative polymerase chain reaction for hepatitis B virus
254. Quantitative monitoring of circulating EpsteinBarr virus DNA for predicting the development of posttransplantation lymphoproliferative disease
255. Cytomegalovirus (CMV) DNA laod in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem cell transplant recipients
256. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real time PCR assay
257. Application of quantittative RT-CR using Taqman technology to evaluate the expression of CK 18 mRNA in various cell lines
258. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations
259. Induction of MAGE-3 expression in lung and esophageal cancer cells
260. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR
261. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness
262. A natural history of melanoma: Serial gene expression analysis
263. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
264. Assays for monitoring cellular immune responses to active immunotherapy of cancer
265. Direct functional analysis of epitope-specific CD8+ T cells in peripheral blood
266. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
267. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond
268. Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation
269. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity
270. Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry
271. Flow cytometric determination of intracellular or secreted IFN-gamma for quantification of antigen reactive T cells
272. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life
273. Counting antigenspecific CD8 T cells: A reevaluation of bystander activation during viral infection
274. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
275. Skewed maturation of memory H/V-specific CD8 T lymphocytes
276. - effector subset exerting ex-vivo tumor-specific cytolytic activity
277. Advances in immunology: T-cell function and migration - Two sides of the same coin